Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Dec;53(1):1827-1838.
doi: 10.1080/07853890.2021.1991591.

Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis

Xing Li  1 , Lijiang Gu  1 , Yuhang Chen  1 , Yue Chong  1 , Xinyang Wang  1   2   3 , Peng Guo  1   2   3 , Dalin He  1   2   3
Affiliations
Meta-Analysis

Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis

Xing Li et al. Ann Med. 2021 Dec.

Abstract

Objective: Systemic immune-inflammation index (SII) has been reported in numerous studies to effectively predict the survival outcomes of urinary system cancers; however no agreement has been reached. This meta-analysis aimed to explore the prognostic significance of pre-treatment SII in tumours of the urinary system.

Methods: Relevant published articles were selected from Web of Science, PubMed, Embase, and the Cochrane Library up to 30 August 2020. The hazard ratios (HRs) with 95% confidence intervals (CIs) were computed to estimate the associations of pre-treatment SII with overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS) in urinary system cancers.

Results: 13 papers were included in our meta-analysis. From the combined data, we found that a high pre-treatment SII indicated a markedly worse OS (HR = 1.98; 95% CI: 1.75-2.23; p < .001), PFS (HR: 2.08; 95% CI: 1.32-3.26; p = .002), and CSS (HR: 2.41, 95% CI: 1.73-3.35, p < .001). Additionally, patients with an elevated SII value might have undesirable pathological characteristics, including a large tumour size, a poor differentiation grade, and an advanced tumour stage (all p < .001).

Conclusions: Pre-treatment SII could be used as a non-invasive and promising biomarker to indicate the prognosis of urinary system cancer patients.KEY MESSAGES:This meta-analysis evaluates the predictive value of systemic immune-inflammation index (SII) for patients with urinary system cancer.A high pre-treatment SII indicates a poor prognosis.SII can serve as a promising non-invasive biomarker to help clinicians assess the prognosis and develop treatment strategies for urinary system cancer patients.

Keywords: Urinary system cancers; meta-analysis; prognosis; systemic immune-inflammation index.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Flow diagram of the study selection process.
Figure 2.
Figure 2.
Forest plot reflecting the prognostic significance of SII for survival in patients (A, OS; B, PFS; C, CSS).
Figure 3.
Figure 3.
Forest plots showing the correlations between SII and clinicopathological factors (A, Age: binary variables; B, Age: continuous variables; C, Gender; D, tumour size; E, differentiation grade; F: tumour stage).
Figure 4.
Figure 4.
Detection of publication bias for meta-analysis of survival outcomes (A, OS: Begg’s funnel plot; B, OS: Filled funnel plot with “trim-and-fill” method; C, PFS; D, CSS).
Figure 5.
Figure 5.
Sensitivity analysis of the relationship between SII and survival outcomes (A, OS; B, PFS; C, CSS).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Antoni S, Ferlay J, Soerjomataram I, et al. . Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. - PubMed
    1. Wong MC, Goggins WB, Wang HH, et al. . Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–874. - PubMed
    1. Siegel RL, Miller KD, Jemal A.. Jemal A: cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. - PubMed
    1. Culp MB, Soerjomataram I, Efstathiou JA, et al. . Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52. - PubMed
    1. Palumbo C, Pecoraro A, Knipper S, et al. . Contemporary age-adjusted incidence and mortality rates of renal cell carcinoma: analysis according to gender, race, stage, grade, and histology. Eur Urol Focus. 2021;7(3):644–652. - PubMed

Publication types

LinkOut - more resources